Author

T. Capraz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

A. Mirazimi· 2 shared C. Oostenbrink· 2 shared G. Wirnsberger· 2 shared J. M. Penninger· 2 shared J. W. Perthold· 2 shared A. Bergthaler· 1 shared A. Hagelkruys· 1 shared A. Hladik· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. Mirazimi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Proteomic profiling identifies Serpin B9 as mediator of resistance to CAR T-cell and bispecific antibody treatment in B-cell lymphoma

B. J. Brinkmann, T. Capraz, T. Roider, M. Knoll, C. Kolb, Y. Liu, A.-E. Angeli-Terzidou, N. Paramasivam, V. Eckstein, T. Sauer, M. Schmitt, A. Rosenwald, C. Mueller-Tidow, W. Huber, S. Dietrich

bioRxiv · Jun 26, 2023 · PreprintCancer Biology

Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor

T. Capraz, N. F. Kienzl, E. Laurent, J. W. Perthold, E. Foederl-Hoebenreich, C. Gruenwald-Gruber, D. Maresch, V. Monteil, J. Niederhoefer, G. Wirnsberger, A. Mirazimi, K. Zatloukal, L. Mach, J. M. Penninger, C. Oostenbrink, J. Stadlmann

This study engineers ACE2 glycosylation to enhance its binding to SARS-CoV-2 Spike protein, resulting in a more potent decoy receptor for COVID-19 treatment.

bioRxiv · Aug 31, 2021Biochemistry

ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology

R. Gawish, P. Starkl, L. Pimenov, A. Hladik, K. Lakovits, F. Oberndorfer, S. J. F. Cronin, A. Ohradanova-Repic, G. Wirnsberger, B. Agerer, L. Endler, T. Capraz, J. W. Perthold, A. Hagelkruys, N. Montserrat, , S. Knapp

This paper develops a mouse-adapted SARS-CoV-2 strain, maVie16, to model COVID-19 in mice, showing that ACE2 is critical for disease and that blocking TNF/IFNγ reduces immunopathology.

bioRxiv · Aug 9, 2021Immunology